6 assets in Dedifferentiated Chondrosarcoma

Therapeutic assets addressing Dedifferentiated Chondrosarcoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Atezolizumab Dedifferentiated Chondrosarcoma	National Cancer Institute (NCI)	P2	CCC (53)
Cyclophosphamide Dedifferentiated Chondrosarcoma	M.D. Anderson Cancer Center	P2	CCC (53)
Fludarabine Dedifferentiated Chondrosarcoma	M.D. Anderson Cancer Center	P2	CCC (53)
Ipilimumab Dedifferentiated Chondrosarcoma	M.D. Anderson Cancer Center	P2	CCC (53)
Lifileucel Dedifferentiated Chondrosarcoma	M.D. Anderson Cancer Center	P2	CCC (53)
Nivolumab Dedifferentiated Chondrosarcoma	M.D. Anderson Cancer Center	P2	CCC (53)